Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001266047 | SCV001444219 | uncertain significance | Inborn genetic diseases | 2020-01-30 | criteria provided, single submitter | clinical testing | The alteration results in an amino acid change:_x000D_ _x000D_ The c.2162A>C (p.K721T) alteration is located in exon 3 (coding exon 2) of the ASH1L gene. This alteration results from a A to C substitution at nucleotide position 2162, causing the lysine (K) at amino acid position 721 to be replaced by a threonine (T). The alteration is rare in population databases:_x000D_ _x000D_ Based on data from the Genome Aggregation Database (gnomAD), the ASH1L c.2162A>C alteration was observed in 0.0004% (1/249964) of total alleles studied. The altered amino acid is conserved throughout evolution:_x000D_ _x000D_ The p.K721 amino acid is conserved in available vertebrate species. The alteration is predicted inconclusive by in silico modeling:_x000D_ _x000D_ The in silico prediction for the p.K721T alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Revvity Omics, |
RCV003135908 | SCV003825087 | uncertain significance | Intellectual disability, autosomal dominant 52 | 2021-03-19 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV003135908 | SCV003834931 | uncertain significance | Intellectual disability, autosomal dominant 52 | 2021-03-06 | criteria provided, single submitter | clinical testing | |
| Genome- |
RCV003135908 | SCV004050422 | uncertain significance | Intellectual disability, autosomal dominant 52 | 2023-04-11 | criteria provided, single submitter | clinical testing |